MIT Institute for Medical Engineering and Science (IMES)

What MIT Institute for Medical Engineering and Science (IMES) does

IMES is an academic research institute within the Massachusetts Institute of Technology that operates at the intersection of engineering, science, and medicine. Founded in 2012 and headquartered at 77 Massachusetts Avenue, Cambridge, Massachusetts, the institute serves as the academic home for the Harvard-MIT Health Sciences and Technology (HST) program, which has operated for more than 50 years. IMES delivers three principal educational programs—the Medical Engineering and Medical Physics (MEMP) PhD, the HST MD track, and the Graduate Education in Medical Sciences (GEMS) Certificate—and supports more than 300 MD/PhD students and 2,100+ alumni alongside 100+ affiliated faculty drawn jointly from MIT and Harvard.

The institute's research portfolio spans nine focus areas: biomedical materials, drug delivery, medical devices, imaging, computational biology, synthetic biology, neuroscience, clinical research, and AI/ML applications in medicine. Core research platforms include the Seq-Well single-cell sequencing technology (Shalek lab), the Antibiotics-AI deep-learning discovery pipeline (Collins lab, trained on 38,650 molecules and used to virtually screen approximately 6 million compounds), multimodal neuroimaging tools, and synthetic biology constructs. Faculty-led commercialization activity includes Ellen Roche's Spheric Bio spinout (medical devices) and James Collins's synthetic biology IP licensed to more than 25 biotech, pharmaceutical, and medical device companies.

IMES's economic model is institutional rather than commercial. Operating funds derive primarily from federal research grants (NIH, NSF), private foundation support, student tuition routed through MIT and Harvard, and technology licensing royalties. Leadership transitioned to Alex Shalek in August 2024, following prior terms by Arup Chakraborty (founding director) and Elazer Edelman (interim director). The institute's strategic positioning depends heavily on its dual Harvard-MIT institutional relationships and access to affiliated teaching hospitals.

Name

MIT Institute for Medical Engineering and Science (IMES)

Legal name

MIT Institute for Medical Engineering and Science

Website

https://imes.mit.edu

Company type

Private

Founded year

2012

Operating status

Operating

Short description

MIT IMES is an academic research institute that operates at the intersection of engineering, science, and medicine, housing the Harvard-MIT HST program and serving 300+ MD/PhD students, 100+ faculty, and 2,100+ alumni across nine interdisciplinary research areas.

Ownership category

akta.pro rank

Product category

Academic Biomedical Research and Medical Engineering Education

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Colleges, Universities, and Professional Schools (6113), Medical and Diagnostic Laboratories (62151)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Biomedical engineering research
• Medical engineering education
• Health sciences technology
• Translational medicine research
• Medical physics training

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Grant Funding: IMES and its faculty receive substantial funding from federal agencies including NIH, NSF, and private foundations to support research programs.
2. Tuition and Academic Fees: Revenue from MD, PhD, and graduate certificate programs through the HST academic program.
3. Technology Licensing: Professor Collins' patented technologies have been licensed by over 25 biotech, pharma and medical devices companies. He has co-founded multiple companies including Synlogic, Senti Biosciences, Sherlock Biosciences, Cellarity, and Phare Bio.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

IMES pioneers research and education at the intersection of engineering, science, and medicine. It delivers interdisciplinary academic programs (MEMP PhD, HST MD, GEMS Certificate) through the Harvard-MIT Health Sciences and Technology program, and conducts research across nine focus areas including biomaterials, computational biology, drug delivery, medical devices, neuroscience, and imaging. The institute also develops and licenses proprietary research platforms such as the Seq-Well single-cell RNA-Seq platform and machine learning pipelines for antibiotic discovery.

Product overview

MIT IMES is MIT's academic research institute that serves as the home for the Harvard-MIT Health Sciences and Technology (HST) program. The institution offers three main educational programs: the Medical Engineering and Medical Physics (MEMP) PhD Program, the HST MD Program, and the Graduate Education in Medical Sciences (GEMS) Certificate. Research activities span nine focus areas including Biomaterials Science, Computational Biology, Drug Delivery, Medical Devices, Neuroscience, and Imaging. The institute also developed the Seq-Well single-cell RNA-Seq platform for biomedical research.

Differentiator

Problem solved

Functional benefit

Products and services

• Harvard-MIT Health Sciences and Technology (HST) Program
• Medical Engineering and Medical Physics (MEMP) PhD Program
• HST MD Program
• Graduate Education in Medical Sciences (GEMS) Certificate
• Seq-Well Single-Cell RNA-Seq Platform
• IMES Distinguished Speaker Series

Quantifiable outcome

• 54 clinician-scientists graduated in 2026
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• Harvard UniversitycoreStrategic or Co-development Partner · 1 January 2012Harvard-MIT Health Sciences and Technology (HST) program is an interdisciplinary collaboration between MIT and Harvard, established in 2012 when IMES was founded. The program educates innovators cultivating scientific, engineering, and clinical leaders who improve human health.
• Boston-area Teaching HospitalscoreStrategic or Co-development PartnerThe HST program includes clinical training and research collaborations with Massachusetts General Hospital, Brigham and Women's Hospital, and other Boston-area teaching hospitals for hands-on medical education.
• Broad Institute of MIT and HarvardcoreTechnology or IntegrationIMES faculty including James Collins and Alex Shalek hold Institute Member positions at the Broad Institute. Research collaborations on genomics, synthetic biology, and infectious disease research.
• Ragon Institute of MGH, MIT, and HarvardcoreStrategic or Co-development PartnerAlex Shalek is a Member of the Ragon Institute, collaborating on immunology and infectious disease research. IMES faculty participate in research focused on HIV, tuberculosis, and other infectious diseases.
• Center for Clinical and Translational Research (CCTR)majorStrategic or Co-development PartnerCCTR is housed at MIT/IMES and supports clinical and translational research initiatives with facilities and resources for researchers.
• Center for Microbiome Informatics and Therapeutics (CMIT)majorStrategic or Co-development PartnerCMIT is affiliated with IMES and focuses on microbiome research including work by faculty like Tami Lieberman on skin microbiome.
• MIT linQmajorStrategic or Co-development PartnerMIT linQ supports innovation and entrepreneurship in health technologies, connecting IMES researchers to industry and clinical translation.
• Wyss Institute for Biologically Inspired Engineering at Harvard UniversitycoreStrategic or Co-development PartnerJames Collins is a Core Founding Faculty member. Collaboration on AI-driven antibiotic discovery including the Antibiotics-AI Project. Joint research published on machine learning for antibiotic-resistant gonorrhea.
• Mass General BrighamcoreStrategic or Co-development PartnerMIT-MGB Seed Program launched with support from Analog Devices Inc. to fund joint research projects advancing technology and clinical research. Alex Shalek holds Assistant in Immunology position at MGB.
• Spheric BiominorOthersEllen Roche co-founded Spheric Bio, a medical device startup developing a minimally invasive heart implant aimed at preventing strokes. Won Faculty Founders Initiative Grand Prize 2022 and Lab Central Ignite Golden Ticket.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Allen Institute: Non-profit biomedical research organization with large-scale team science, shared technology platforms, and translational outputs. Comparable in operating model and mission of advancing science for human health.
• Gladstone Institutes (UCSF): A university-affiliated biomedical research institute with shared faculty, spinout generation, and a disease-focused research mandate. Operates with a similar academic-but-translational orientation as IMES.
• Wyss Institute for Biologically Inspired Engineering: Core research partner with shared faculty (Collins as Core Founding Faculty). It pursues bio-inspired engineering and translational medicine with a strong industry licensing and spinout record, directly comparable to IMES's commercialization pipeline.
• Broad Institute of MIT and Harvard: Core institutional partner and overlapping faculty (Collins and Shalek are Broad Institute Members). It conducts large-scale genomics, chemical biology, and disease research with shared access to MIT/Harvard talent pools, making it the closest organizational analog.
• Harvard-MIT Health Sciences and Technology Program (HST): HST is the joint Harvard-MIT program housed within IMES itself, so it is structurally identical as an interdisciplinary medical engineering and science educational/research program. Included for completeness as the direct unit analog.
• Koch Institute for Integrative Cancer Research at MIT: A sibling MIT research institute focused on cancer but operating with the same model: faculty-led labs, interdisciplinary engineering-medicine research, industry collaborations, and translation programs. Comparable governance and funding structure within MIT.
• Whitehead Institute for Biomedical Research: An MIT-affiliated biomedical research institute with a similar model of faculty-led labs producing high-impact basic science and spinouts (e.g., Alnylam Pharmaceuticals). Comparable in scale and ecosystem positioning.
• Stanford Bio-X: Stanford Bio-X is a comparable interdisciplinary biomedical research institute at Stanford that bridges engineering, medicine, and basic sciences, with similar interdisciplinary seed funding, graduate training programs (e.g., MD-PhD), and industry translation goals.

Emerging players

• Institute for Protein Design (University of Washington): University-based research institute applying computational/AI methods to protein design and biologic discovery with a strong spinout record (e.g., Neoleukin Therapeutics). Overlaps with IMES's AI-for-biologics and synthetic biology portfolio.

Broad incumbents

• Howard Hughes Medical Institute (HHMI): Larger and broader biomedical research funder/operator that supports Investigator faculty at IMES-partner institutions. Operates in the same translational biomedical space with much greater financial scale (~$20B endowment).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MIT_IMES
• Facebookfacebook.com/imesmit
• LinkedInlinkedin.com/company/mit-institute-for-medical-engineering-and-science-imes

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIT Institute for Medical Engineering and Science (IMES)